title: Extracellular adenosine metabolism in immune cells in melanoma.
abstract: Malignant melanoma is characterized by the development of chronic inflammation in the tumor microenvironment, which leads to a strong immunosuppression associated with a rapid tumor progression. Adenosine is considered as one of the main immunosuppressive factors in the tumor environment. It is produced via enzymatic hydrolysis of extracellular ATP by ectonucleotidases CD39 and CD73 localized on cell surface. Using the ret transgenic mouse melanoma model that closely mimics human melanoma, we demonstrated an increased frequency of ectonucleotidase-positive myeloid-derived suppressor cells (MDSCs) in melanoma lesions and lymphoid organs. Furthermore, we observed that conventional CD4(+)FoxP3(-) and CD8(+) T cells infiltrating melanoma lesions of ret transgenic mice were distinctly enriched in the CD39(+)CD73(+) subpopulation that co-expressed also PD-1. Ectonucleotidase expression was also up-regulated in CD4(+) and CD8(+) T cells upon activation. In addition, these ectoenzymes were largely found to be expressed on memory T cell compartment (in particular, on effector memory cells). Our data suggest that extracellular adenosine produced by regulatory T cells (Tregs) and MDSCs can suppress T cell effector functions through paracrine signaling. Another mechanism involves its production also by effector T cells and an inhibition of their anti-tumor reactivity via autocrine signaling as a part of the negative feedback loop. This mode of adenosine signaling could be also used by Tregs and MDSCs to enhance their immunosuppressive activity.
authors.affiliation: Skin Cancer Unit (G300), German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany, v.umansky@dkfz.de.
authors.forename: Viktor
authors.initials: V
authors.lastname: Umansky
authors.forename: Ivan
authors.initials: I
authors.lastname: Shevchenko
authors.forename: Alexandr V
authors.initials: AV
authors.lastname: Bazhin
authors.forename: Jochen
authors.initials: J
authors.lastname: Utikal
mesh_terms: D000241:Adenosine / Q000276:immunology / Q000378:metabolism*; D000818:Animals; D045744:Cell Line, Tumor; D006801:Humans; D008545:Melanoma / Q000276:immunology* / Q000378:metabolism*; D051379:Mice; D012878:Skin Neoplasms / Q000276:immunology* / Q000378:metabolism*; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism*
chemical_list: D000241:Adenosine
references.citation: Int J Oncol. 2008 Mar;32(3):527-35
references.pmid: 18292929
references.citation: J Clin Invest. 2009 May;119(5):1136-49
references.pmid: 19381014
references.citation: J Clin Invest. 2011 Jun;121(6):2371-82
references.pmid: 21537079
references.citation: Prog Neurobiol. 2007 Dec;83(5):263-76
references.pmid: 17804147
references.citation: Annu Rev Immunol. 2012;30:531-64
references.pmid: 22224781
references.citation: Cancer Immunol Immunother. 2011 Mar;60(3):425-31
references.pmid: 21240484
references.citation: Int J Cancer. 2002 May 20;99(3):386-95
references.pmid: 11992407
references.citation: Cancer Immunol Immunother. 2012 Feb;61(2):283-288
references.pmid: 22146892
references.citation: FASEB J. 2009 Jun;23(6):1685-93
references.pmid: 19211924
references.citation: Blood. 2008 Sep 1;112(5):1822-31
references.pmid: 18559975
references.citation: Cancer Immunol Immunother. 2012 Feb;61(2):255-263
references.pmid: 22120756
references.citation: J Exp Med. 2007 Jun 11;204(6):1257-65
references.pmid: 17502665
references.citation: Cancer Res. 2008 Nov 15;68(22):9451-8
references.pmid: 19010920
references.citation: J Clin Invest. 2001 Jul;108(1):131-41
references.pmid: 11435465
references.citation: J Dtsch Dermatol Ges. 2013 Aug;11 Suppl 6:1-116, 1-126
references.pmid: 24028775
references.citation: Expert Opin Biol Ther. 2011 Sep;11(9):1203-14
references.pmid: 21702720
references.citation: Cancer Res. 2007 Jun 15;67(12):5949-56
references.pmid: 17575165
references.citation: Trends Immunol. 2012 May;33(5):231-7
references.pmid: 22487321
references.citation: Nat Rev Immunol. 2011 Mar;11(3):201-12
references.pmid: 21331080
references.citation: Oncogene. 2003 Feb 27;22(8):1206-18
references.pmid: 12606947
references.citation: Eur J Immunol. 2011 Oct;41(10):2955-65
references.pmid: 21770045
references.citation: Eur J Immunol. 2005 Jan;35(1):25-30
references.pmid: 15580654
references.citation: Cancer Immunol Immunother. 2014 Jan;63(1):67-72
references.pmid: 24213679
references.citation: Oncogene. 2010 Sep 30;29(39):5346-58
references.pmid: 20661219
references.citation: Science. 2013 Jan 18;339(6117):286-91
references.pmid: 23329041
references.citation: J Immunol. 2008 Oct 15;181(8):5791-802
references.pmid: 18832739
references.citation: Nat Immunol. 2005 Apr;6(4):345-52
references.pmid: 15785760
references.citation: FASEB J. 2012 Jan;26(1):376-86
references.pmid: 21926236
references.citation: Immunity. 2012 Mar 23;36(3):362-73
references.pmid: 22406269
references.citation: Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17111-6
references.pmid: 21969559
references.citation: Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1547-52
references.pmid: 20080644
references.citation: J Immunol. 2012 Apr 1;188(7):2929-30; author reply 1930
references.pmid: 22442488
references.citation: Oncoimmunology. 2013 Sep 1;2(9):e26246
references.pmid: 24319640
references.citation: J Biomed Biotechnol. 2012;2012:485156
references.pmid: 23125525
references.citation: Blood. 1997 Aug 15;90(4):1600-10
references.pmid: 9269779
references.citation: Cancer Res. 2006 Aug 1;66(15):7758-65
references.pmid: 16885379
references.citation: Trends Immunol. 2004 Jan;25(1):33-9
references.pmid: 14698282
references.citation: Semin Cancer Biol. 2012 Aug;22(4):335-41
references.pmid: 22414910
references.citation: Immunol Rev. 2011 Jan;239(1):27-44
references.pmid: 21198663
references.citation: Adv Cancer Res. 2010;107:57-117
references.pmid: 20399961
references.citation: Oncoimmunology. 2012 May 1;1(3):326-333
references.pmid: 22737608
references.citation: Structure. 2012 Dec 5;20(12):2161-73
references.pmid: 23142347
references.citation: J Biol Chem. 1997 Oct 10;272(41):25881-9
references.pmid: 9325320
references.citation: Ann N Y Acad Sci. 1985;451:34-41
references.pmid: 3878120
references.citation: Semin Cancer Biol. 2012 Aug;22(4):307-18
references.pmid: 22387003
references.citation: J Immunol. 2011 Dec 1;187(11):6120-9
references.pmid: 22039302
references.citation: J Biol Chem. 2010 Mar 5;285(10):7176-86
references.pmid: 19858205
references.citation: Immunity. 2009 May;30(5):636-45
references.pmid: 19464986
references.citation: Carcinogenesis. 2012 May;33(5):949-55
references.pmid: 22425643
references.citation: Curr Opin Immunol. 2010 Apr;22(2):238-44
references.pmid: 20171075
references.citation: Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7
references.pmid: 16916931
references.citation: J Immunol. 2009 Apr 15;182(8):4499-506
references.pmid: 19342621
references.citation: Cancer Res. 1997 Jul 1;57(13):2602-5
references.pmid: 9205063
references.citation: Semin Cancer Biol. 2012 Aug;22(4):298-306
references.pmid: 22414911
references.citation: Circ Res. 1997 Aug;81(2):154-64
references.pmid: 9242176
references.citation: Purinergic Signal. 2006 Jun;2(2):343-50
references.pmid: 18404474
references.citation: J Immunol. 2010 Aug 15;185(4):1993-8
references.pmid: 20686167
references.citation: Exp Cell Res. 2002 May 15;276(1):90-100
references.pmid: 11978011
references.citation: Cancer Res. 2011 Apr 15;71(8):2892-900
references.pmid: 21292811
references.citation: Oncogene. 1998 Oct 8;17(14):1885-8
references.pmid: 9778055
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):252-64
references.pmid: 22437870
references.citation: Cancer Res. 2010 Mar 15;70(6):2245-55
references.pmid: 20179192
references.citation: Nat Rev Cancer. 2010 Mar;10(3):181-93
references.pmid: 20168319
references.citation: Sci Signal. 2011 Mar 01;4(162):ra12
references.pmid: 21364186
references.citation: Clin Cancer Res. 2008 Oct 1;14(19):5947-52
references.pmid: 18829471
references.citation: Cancer Treat Rev. 2013 Dec;39(8):879-85
references.pmid: 23725878
references.citation: J Biomed Biotechnol. 2012;2012:473712
references.pmid: 23133312
references.citation: Curr Med Chem. 2011;18(34):5217-23
references.pmid: 22087822
references.citation: Clin Cancer Res. 2012 Sep 15;18(18):4877-82
references.pmid: 22718858
references.citation: J Clin Oncol. 2009 Dec 20;27(36):6199-206
references.pmid: 19917835
references.citation: Curr Opin Immunol. 2011 Apr;23(2):286-92
references.pmid: 21185705
references.citation: J Immunol. 2005 Jan 15;174(2):1073-80
references.pmid: 15634932
references.citation: Annu Rev Immunol. 2004;22:657-82
references.pmid: 15032592
references.citation: Annu Rev Immunol. 2004;22:745-63
references.pmid: 15032595
references.citation: Cell. 2010 Mar 19;140(6):883-99
references.pmid: 20303878
references.citation: Curr Mol Med. 2010 Jun;10(4):369-73
references.pmid: 20455855
references.citation: Am J Physiol Cell Physiol. 2011 Aug;301(2):C530-9
references.pmid: 21593451
references.citation: Cancer Immunol Immunother. 2010 Oct;59(10):1593-600
references.pmid: 20414655
references.citation: Curr Opin Immunol. 2010 Apr;22(2):231-7
references.pmid: 20144856
references.citation: Ann Oncol. 2009 Aug;20 Suppl 6:vi1-7
references.pmid: 19617292
references.citation: Nat Rev Clin Oncol. 2011 Aug 02;8(10):577-85
references.pmid: 21808266
references.citation: Cancer Res. 2012 May 1;72(9):2190-6
references.pmid: 22396496
references.citation: Cancer Immunol Immunother. 2012 Feb;61(2):275-282
references.pmid: 22120757
references.citation: Nat Rev Cancer. 2009 May;9(5):361-71
references.pmid: 19343034
references.citation: Sci Signal. 2010 Jun 08;3(125):ra45
references.pmid: 20530802
references.citation: Cancer Res. 2007 Sep 15;67(18):8429-32
references.pmid: 17875679
references.citation: Nat Rev Immunol. 2012 Mar 22;12(4):253-68
references.pmid: 22437938
references.citation: Trends Immunol. 2011 Jan;32(1):19-25
references.pmid: 21067974